# Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

> **NCT02090465** · — · COMPLETED · sponsor: **LEO Pharma** · enrollment: 840 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Ingenol Mebutate

## Key facts

- **NCT ID:** NCT02090465
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 840 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090465, "Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02090465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*